🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Agilon Health shares plunge 28% on weak Q3 results, lowered guidance

Published 11/08/2024, 05:52 AM
AGI
-

AUSTIN, Texas - Agilon Health Inc. (NYSE:AGL) saw its shares tumble 28% after reporting disappointing third-quarter results and cutting its full-year profit outlook. The healthcare company cited challenges in the Medicare Advantage environment and unexpected costs as key factors impacting its performance.

For the third quarter, Agilon Health reported a loss of -$0.29 per share, significantly wider than the analyst estimate of -$0.10. Revenue came in at $1.45 billion, slightly below the consensus of $1.47 billion but up 28% YoY.

The company's Medicare Advantage membership grew 37% YoY to 525,000, while total members on the Agilon platform increased 39% to 657,000.

The quarter's results were negatively impacted by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses. These factors led to a gross profit loss of $64 million, compared to a positive $37 million in the same quarter last year.

"Our Q3 results show that our membership is growing across our 26 partnerships, and it also highlights why we are taking necessary actions to strengthen execution within our platform and proactively manage the challenging Medicare Advantage environment," said Steve Sell, CEO of Agilon Health.

In response to these challenges, Agilon Health announced plans to exit two unprofitable partnerships and other payor contracts by the end of 2024.

Looking ahead, the company provided mixed guidance. For the fourth quarter, Agilon Health expects revenue between $1.51 billion and $1.52 billion, above the consensus of $1.46 billion.

For the full year 2024, the company forecasts revenue of $6.05 billion to $6.06 billion, slightly higher than the analyst estimate of $6.02 billion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.